U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C19H30N5O10P.C4H4O4
Molecular Weight 635.5149
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of TENOFOVIR DISOPROXIL FUMARATE

SMILES

OC(=O)\C=C\C(O)=O.CC(C)OC(=O)OCOP(=O)(CO[C@H](C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C

InChI

InChIKey=VCMJCVGFSROFHV-WZGZYPNHSA-N
InChI=1S/C19H30N5O10P.C4H4O4/c1-12(2)33-18(25)28-9-31-35(27,32-10-29-19(26)34-13(3)4)11-30-14(5)6-24-8-23-15-16(20)21-7-22-17(15)24;5-3(6)1-2-4(7)8/h7-8,12-14H,6,9-11H2,1-5H3,(H2,20,21,22);1-2H,(H,5,6)(H,7,8)/b;2-1+/t14-;/m1./s1

HIDE SMILES / InChI
Molecular Formula C19H30N5O10P
Molecular Weight 519.4428
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C4H4O4
Molecular Weight 116.0722
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:28:20 UTC 2023
Edited
by admin
on Fri Dec 15 15:28:20 UTC 2023
Record UNII
OTT9J7900I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TENOFOVIR DISOPROXIL FUMARATE
EMA EPAR   HSDB   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD   WHO-IP  
USAN  
Official Name English
TENOFOVIR DISOPROXIL FUMARATE [JAN]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF ODEFSEY
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [HSDB]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF TEMIXYS
Common Name English
GS-4331-05
Code English
TENOFOVIR DISOPROXIL FUMARATE [USAN]
Common Name English
9-((R)-2-((BIS(((ISOPROPOXYCARBONYL)OXY)-METHOXY)PHOSPHINYL)METHOXY)PROPYL)ADENINE FUMARATE (1:1)
Common Name English
TENOFOVIR DF
Common Name English
TENOFOVIR (AS DISOPROXIL FUMARATE)
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [VANDF]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF STRIBILD
Brand Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF TRUVADA
Brand Name English
GSK548470
Code English
TENOFOVIR DISOPROXIL FUMARATE [WHO-IP]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF EVIPLERA
Brand Name English
Tenofovir disoproxil fumarate [WHO-DD]
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [MI]
Common Name English
TENOFOVIRI DISOPROXILI FUMARAS [WHO-IP LATIN]
Common Name English
EVIPLERA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
TENOFOVIR DISOPROXIL FUMARATE [EMA EPAR]
Common Name English
ATRIPLA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Common Name English
TEMIXYS COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Common Name English
VIREAD
Brand Name English
TENOFOVIR DISOPROXIL FUMARATE [ORANGE BOOK]
Common Name English
GSK-548470
Code English
ODEFSEY COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Common Name English
TENOFOVIR DISOPROXIL FUMARATE [MART.]
Common Name English
STRIBILD COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
PMPA-PRODRUG
Code English
TENOFOVIR DISOPROXIL FUMARATE [USP-RS]
Common Name English
Bis(hydroxymethyl) [[(R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phosphonate, bis(isopropyl carbonate) (ester), fumarate (1:1)
Common Name English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT OF ATRIPLA
Common Name English
DELSTRIGO COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
GS-4331-05-
Code English
PMPA PRODRUG
Code English
TENOFOVIR DISOPROXIL FUMARATE COMPONENT DELSTRIGO
Brand Name English
TRUVADA COMPONENT TENOFOVIR DISOPROXIL FUMARATE
Brand Name English
(R)-5-((2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-2,4,6,8-TETRAOXA-5-PHOSPHANONANEDIOIC ACID, BIS(1-METHYLETHYL) ESTER, 5-OXIDE, (E)-2-BUTENEDIOATE (1:1)
Common Name English
VIREA
Brand Name English
TDF
Common Name English
9-((R)-2-((BIS(((ISOPROPOXYCARBONYL)OXY)METHOXY)PHOSPHINYL)METHOXY)PROPYL)ADENINE FUMARATE (1:1)
Common Name English
Classification Tree Code System Code
EMA ASSESSMENT REPORTS VIREAD (AUTHORIZED: HEPTATITS B, CHRONIC)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
NCI_THESAURUS C97452
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EU-Orphan Drug EU/3/14/1419
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS EVIPLERA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
FDA ORPHAN DRUG 538416
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS ATRIPLA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
FDA ORPHAN DRUG 559316
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS TRUVADA (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 6.4.2.1
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
EMA ASSESSMENT REPORTS VIREAD (AUTHORIZED: HIV INFECTIONS)
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
Code System Code Type Description
CAS
202138-50-9
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
MERCK INDEX
m10559
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY Merck Index
CHEBI
63717
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
RXCUI
322248
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY RxNorm
EPA CompTox
DTXSID5050426
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
TENOFOVIR DISOPROXIL FUMARATE
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY Description: White to almost-white, crystalline powder. Solubility: Slightly soluble in water, soluble in methanol, very slightly soluble in dichloromethane. Category: Antiretroviral (Nucleotide Reverse Transcriptase Inhibitor). Storage: Tenofovir disoproxil fumarate should be kept in a tightly closed container, protected from light and stored at a temperature between 2?8 ?C. Additional information: Tenofovir disoproxil fumarate may exhibit polymorphism. Definition: Tenofovir disoproxil fumarate contains not less than 98.5% and not more than 101.0% of tenofovir disoproxil fumarate(C19H30N5O10P,C4H4O4), calculated with reference to the anhydrous substance. Manufacture: The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 5 ppm for the mutagenic impurity 9-propenyladenine (impurity K), which may be a synthesis related substance, using a suitable method; ? a limit of not more than 1.0% for the tenofovir disoproxil (S)-enantiomer (impurity G) using a suitable chiral chromatographic method.
DAILYMED
OTT9J7900I
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
NCI_THESAURUS
C47747
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
EVMPD
SUB12607MIG
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
SMS_ID
100000092141
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
PUBCHEM
6398764
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
CHEBI
63718
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
USAN
KK-89
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
DRUG BANK
DBSALT000172
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
RS_ITEM_NUM
1643656
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
FDA UNII
OTT9J7900I
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
ChEMBL
CHEMBL1538
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
HSDB
7165
Created by admin on Fri Dec 15 15:28:20 UTC 2023 , Edited by admin on Fri Dec 15 15:28:20 UTC 2023
PRIMARY
Related Record Type Details
Structure of TENOFOVIR DISOPROXIL
PARENT -> SALT/SOLVATE
Related Record Type Details
Structure of TENOFOVIR DISOPROXIL DIMER
IMPURITY -> PARENT
Amount Not Specified
Structure of ETHYL 1-METHYLETHYL (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-5-OXO-2,4,6,8-TETRAOXA-5-.LAMBDA.5-PHOSPHANONANEDIOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of TENOFOVIR MONO POC DIMER
IMPURITY -> PARENT
Structure of TENOFOVIR ISOPROXIL MONOESTER
IMPURITY -> PARENT
In the chromatogram obtained with solution (1) the area of any peak due to tenofovir monosoproxil (impurity A) is not greater than twice the area of the principal peak obtained with solution (2) (1.0%).
Structure of TENOFOVIR DISOPROXIL (S)-ENANTIOMER
IMPURITY -> PARENT
The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 1.0% for the tenofovir disoproxil (S)-enantiomer (impurity G) using a suitable chiral chromatographic method.
Structure of (R)-ISOPROPYL (9-(2-((BIS(((ISOPROPOXYCARBONYL)OXY)METHOXY)PHOSPHORYL)METHOXY)PROPYL)-9H-PURIN-6-YL)CARBAMATE
IMPURITY -> PARENT
Structure of (1-METHYLETHYL) (8R)-5-HYDROXY-8-METHYL-9-(6-(((1-METHYLETHOXY)CARBONYL)AMINO)-9H-PURIN-9-YL)-5-OXO-2,4,7-TRIOXA-5-.LAMBDA.5-PHOSPHANONANOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of 1-METHYLETHYL PROPYL (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-5-OXO-2,4,6,8-TETRAOXA-5-.LAMBDA.5-PHOSPHANONANEDIOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of Mono-POC Isopropyl Tenofovir fumarate
IMPURITY -> PARENT
Structure of TENOFOVIR MONOSOPROXIL DIMER
IMPURITY -> PARENT
Amount Not Specified
Structure of Mono-POC Isopropyl Tenofovir
IMPURITY -> PARENT
Amount Not Specified
Structure of (1-METHYLETHYL) (5RS,8R)-9-(6-AMINO-9H-PURIN-9-YL)-5-METHOXY-8-METHYL-5-OXO-2,4,7-TRIOXA-5-.LAMBDA.5-PHOSPHANONANOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of (1-METHYLETHYL) (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-10-METHYL-5,9-DIOXO-2,4,6,8-TETRAOXA-10-AZA-5-.LAMBDA.5-PHOSPHAUNDECANOATE
IMPURITY -> PARENT
Amount Not Specified
Structure of 9-(1E)-1-Propen-1-yl-9H-purin-6-amine
IMPURITY -> PARENT
The production method is validated to ensure that the substance, if tested, would comply with: ? a limit of not more than 5 ppm for the mutagenic impurity 9-propenyladenine (impurity K), which may be a synthesis related substance, using a suitable method.
Structure of TENOFOVIR DI AND MONOSOPROXIL HETERODIMER
IMPURITY -> PARENT
Amount Not Specified
Structure of TENOFOVIR ANHYDROUS
IMPURITY -> PARENT
Structure of METHYL (1-METHYLETHYL) (5RS)-5-(((1R)-2-(6-AMINO-9H-PURIN-9-YL)-1-METHYLETHOXY)METHYL)-5-OXO-2,4,6,8-TETRAOXA-5-.LAMBDA.5-PHOSPHANONANEDIOATE
IMPURITY -> PARENT
Amount Not Specified
Related Record Type Details
Structure of TENOFOVIR ANHYDROUS
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966